JOURNAL OF PRACTICAL HEPATOLOGY ›› 2015, Vol. 18 ›› Issue (1): 113-119.doi: 10.3969/j.issn.1672-5069.2015.01.032
• Orignal Article • Previous Articles Next Articles
Received:
2014-10-29
Online:
2015-12-17
Published:
2015-12-17
Contact:
Zhuang Hui,E-mail:zhuangbmu@126.com;Weng Xinhua, xinhua_weng@fudan.edu.cn
[1] Werle-Lapostolle B,Bowden S,Locarnini S,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology,2004,126(7):1750-1758. [2] Busca A,Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J,2014,11:22. [3] Glebe D. Recent advances in hepatitis B virus research:a German point of view. World J Gastroenterol,2007,13(1):8-13. [4] Chan C,Abu-Raddad E,Golor G,et al. Clinical phamacokinetics of alamifovir and its metabolites.Antimicrob Agents Chemother, 2005,49(5):1813-1822. [5] Bertoletti A,Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection. Gut,2012,61(12):1754-1764. [6] Marcellin P,Asselah T. Long-term therapy for chronic hepatitis B:hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol,2013,28(6):912-923. [7] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南 (2010年版). 中国病毒病杂志,2011,1(1):9-23. [8] European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol,2012,57(1):167-185. [9] Liaw YF,Kao JH,Piratvisuth T,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int,2012,6 (3):531-561. [10] Lok AS,McMahon BJ. Chronic hepatitis B:update 2009. Hepatology,2009,50(3):661-662. [11] Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis,2004,24 Suppl 1:3-10. [12] Levrero M,Pollicino T,Petersen J,et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol,2009,51(3):581-592. [13] Wei Y,Neuveut C,Tiollais P,et al. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol (Paris), 2010,58(4):267-272. [14] Abu-Amara M,Feld JJ. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma Semin Liver Dis,2013,33(2):157-166. [15] Wursthorn K,Lutgehetmann M,Dandri M,et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology,2006,44(3):675-684. [16] Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res,2004,64(1):1-15. [17] Balsano C,Alisi A. Viral hepatitis B:established and emerging therapies. Curr Med Chem,2008,15(9):930-939. [18] Fung J,Lai CL,Seto WK,et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother,2011,66(12):2715-2725. [19] Kamiya N. The mechanisms of action of antivials against hepatitis B virus infection. J Antimicrob Chemother,2003,51(5):1085-1089. [20] Gish R,Jia JD,Locarnini S,et al. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis,2012,12(4):341-353. [21] Reijnders JG,Janssen HL. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs:is the glass half full or half empty Hepatology,2013,58(6):1885-1887. [22] Chang TT,Liaw YF,Wu SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology,2010,52(3):886-893. [23] Marinos G,Naoumov NV,Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology,1996,24(5):991-995. [24] Boni C,Bertolatti A,Penna A,et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest,1998,102(5):968-975. [25] Boni C,Penna A,Ogg GS,et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy. Hepatology,2001,33(4):963-971. [26] Evans A,Riva A,Cooksley H,et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B:impact of hepatitis B e-antigen seroconversion. Hepatology,2008,48(3):759-769. [27] Zhang JY,Song CH,Shi F,et al. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One,2010,5(11):e13869. [28] Yeh CT,Hsu CW,Chen YC,et al.你Withdrawal of lamivudine in HBeAgpositivechronic hepatitis B patients afterachieving effective maintained virologicalsuppression. J Clin Virol,2009,45(2):114-118. [29] Liaw YF,Leung N,Kao JH,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update. Hepatol Int,2008,2(3):263-283. [30] Lee HW,Lee HJ,Hwang JS,et al. Lamivudinemaintenance beyond one yearafter HBeAg seroconversion is a majorfactor for sustained virologic response inHBeAg-positive chronic hepatitis B. Hepatology,2010,51(2):415-421. [31] Lok AS,McMahon BJ. Chronic hepatitis B:update of recommendations. Hepatology,2004,39(3):857-861. [32] Liang Y,Jiang J,Su M,et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther,2011,34(3):344-352. [33] Pan XF,Zhang K,Yang XA,et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One,2013,8(7):e68568. [34] LiawYF,Leung N,Guan R,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2005 update . Liver Int,2005,25(3):472-489. [35] Jiang JN,Huang ZL,He LX,et al. Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. J Clin Gastroenterol,2014. [Epub ahead of print] [36] Jeng WJ,Sheen IS,Chen YC,et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology,2013,58(6):1888-1896. [37] Seto WK,Hui AJ,Wong WS,et al. Treatment cessation of entecavir in Asian patientswith hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study. Gut,2014. [Epub ahead of print] [38] Song BC,Suh DJ,Lee HC,et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology,2000,32(4 Pt 1):803-806. [39] Reijnders JG,Perquin MJ,Zhang NP,et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigenseroconversion in most patients with chronic hepatitis B. Gastroenterology,2010,139(2):491-498. [40] Fung SK,Wong F,Hussain M,et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat,2004,11(5):432-438. [41] Chan HL,Wang H,Niu J,et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B:a double-blind,placebo-controlled trial. Antivir Ther,2007,12(3):345-353. [42] Hadziyannis SJ,Sevastianos V,Rapti I,et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology,2012,143(3):629-636. [43] Liu F,Wang L,Li XY,et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria:a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol,2011,26(3):456-460. [44] Dienstag JL,Goldin RD,Heathcote EJ,et al. Histological outcome during long-term lamivudine therapy. Gastroenterology,2003,124(1):105-117. [45] Xu B,Lin LY,Xu GG,et al. Long-term lamivudine treatment achieves regression ofadvanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. JGastroenter Hepatol,2014. [Epub ahead of print] [46] Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al. Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years. Gastroenterology,2006,131(6):1743-1751. [47] Marcellin P,Chang TT,Lim SG,et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology,2008,48(3):750-758. [48] Liaw YF. Reversal of cirrhosis:an achievable goal of hepatitis B antiviral therapy. J Hepatol,2013,59(4):880-881. [49] Schiff ER,Lee SS,Chao YC,et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol,2011,9(3):274-276 [50] Liaw YF,Raptopoulou-Gigi M,Cheinquer H,et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompesation:a randomized,open-label study. Hepatology,2011,54(1):91-100. [51] Liaw YF,Sheen IS,Lee CM,et al. Tenofovir disoproxil fumarate (TDF),emtricitabine/TDF,and entecavir in patients with decompesated chronic hepatitis B liver disease. Hepatology,2011,53(1):62-72. [52] Yuen MF,Seto WK,Chow DH,et al. Long-term lamivudinetherapy reduces the risk of long-term complicationsof chronic hepatitis B infection even in patients without advanced disease. Antivir Ther,2007,12(8):1295-1303. [53] Liaw YF,Sung JJ,Chow WC,et al. TheCALM Study Group.Lamivudine for patients with chronichepatitis B and advanced liver disease. N Engl J Med,2004,351(15):1521-1531. [54] Matsumoto A,Tanaka E,Rokuhara A,et al. The Inuyama Hepatitis Study Group. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:a multicenter retrospective study of 2795 patients. Hepatol Res,2005,32(3):173-184. [55] Di Marco V,Marzano A,Lampertico P,et al. Italian Association for the Study of the Liver(AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology,2004,40(4):883-891. [56] Sung JJ,Tsoi KK,Wong VW,et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther,2008,28(9):1067-1077. [57] Papatheodoridis GV,Lampertico P,Manolakopoulos S,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review. J Hepatol,2010,53(2):348-356. [58] Eun JR,Lee HJ,Kim TN,et al. Risk assessment for thedevelopment of hepatocellular carcinoma:according toon-treatment viral response during long-term lamivudinetherapy in hepatitis B virus-related liver disease. J Hepatol,2010,53(1):118-125. [59] Su TH,Hu TH,Lin CC,et al. Reduction of hepatocellular carcinoma in hepatitis B related cirrhosis patients with long-term entecavir therapy-an interim report of C-TEAM study. Hepatology,2013,58Suppl 1:301A. [60] Wu CY,Lin JT,Ho HJ,et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study. Gastroenterology,2014,147(1):143-151. [61] Kumada T,Toyoda H,Tada T,et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis. J Hepatology,2013,58(3):427-433. [62] Papatheodoridis GV,Manolakopoulos S,Touloumi G,et al. Virological suppression does not prevent the developmentof hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy:results of the nationwide HEPNET. Greece cohort study . Gut,2011,60(8):1109-1116. [63] Fattovich G,Bortolotti F,Donato F. Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors. J Hepatology,2008,48(2):335-352. [64] Papatheodoridis G,Manolakopoulos S,Touloumi G,et al. Hepatocellularcarcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-) with or without cirrhosis treated with entecavir: results of the nationwide HepNet Greece Cohort Study. J Hepatol,2013, 58Suppl 1:S312. [65] Lampertico P,Soffredini R,Yurdaydin C,et al. Four years of tenofovir monotherapy for NUC naive field practice European patients suppress HBV replication in most patients with a favourable renal safety profile but do not prevent HCC in patients with or without cirrhosis. Hepatology,2013,58Suppl 1:653A. [66] Papatheodoridis GV,Dalekos GN,Yurdaydin C,et al. Risk and risk factors of hepatocellular carcinoma(HCC) in Caucasian chronic hepatitis B(CHB) patients with or without cirrhosis treated with entecavir(ETV) or tenofovir(TDF). Hepatology,2013,58Suppl 1:302A. [67] Cho JY,Paik YH,Sohn W,et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease . Gut,2014. [68] Lampertico P,Soffredini R,Vigano M,et al. 5-year entecavir treatment in NUC-naive,field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhosis. J Hepatol,2013,58Suppl 1:S306. [69] Hosaka T,Suzuki F,Kobayashi M,et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology,2013,58(1):98-107. [70] Wong GL,Chan HL,Chan HY,et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology,2013,144(5):933-944. [71] Kim WR,BergT,Loomb R,et al. Long-term tenofovir disoproxil fumarate therapy and the risk of hepatocellular carcinoma. J Hepatol,2013,58Suppl 1:S19. [72] Hilleret MN,Larrat S,Stanke-Labesque F,et al. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough J Hepatol,2011,55(6):1468-1469. [73] Berg T,Marcellin P,Zoulim F,et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic hepatitis B virus infection. Gastroenterology,2010,139(4):1207-1217. [74] World Health Organization. Adherence to long-term therapies: evidence for action[EB/OL]. [2014-08-12]. http://www.who.int/chp/knowledge/publications/adherencefull_report.pdf. [75] Chotiyaputta W,Peterson C,Ditah FA,et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol,2011,54(1):12-18. [76] Lee M,Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol,2011,54(1):6-8. [77] Giang L,Sellinger CP,Lee AU. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires . World J Hepatol,2012,4(2):43-49. [78] 孙秘书,王贵强,张伟,等. 拉米夫定经治慢性乙型肝炎患者治疗现状调查分析. 中国预防医学杂志,2012,13(1):18-22. [79] 叶丽华, 胡兆琴, 李正莲. 慢性乙型肝炎患者诊断治疗依从性行为调查. 实用肝脏病杂志,2013,16(2):155-156. [80] An P,Bian L,Yin B,et al. Risk factors of gene-resistantmutations in different nucleosides. Hepato-Gastroenterology,2012,59 (113):228-230. [81] Zeng MD,Mao YM,Yao GB,et al. Five years of treatment with adefovir dipivoxil in Chinese patients withHBeAg-positive chronic hepatitis B . Liv Int,2012,32(1):137-146. [82] Sun J,Xie Q,Tan DM,et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronichepatitis B patients:a randomized,controlled study. Hepatology,2014,59(4):1283-1292. [83] 参加乙型肝炎耐药讨论会专家. 核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理. 中国病毒病杂志,2013,3(1):1-11. [84] Pipili C, Cholongitas E,Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronichepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther,2014,39(1):35-46. [85] Jung YK,Yeon JE,Choi JH,et al. Fanconi’ssyndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver,2010,4(3):389-393. [86] Verhelst D, Monge M,Meynard JL,et al. Fanconi syndrome and renalfailure induced by tenofovir:a first case report. Am J Kidney Dis,2002,40(6):1331-1333. [87] Gaspar G,Monereo A,García-Reyne A,et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS,2004,18(2):351-352. [88] Pol1 S,Lampertico P. First-line treatment of chronic hepatitis B with entecavir ortenofovir in real-life settings:from clinical trials to clinicalpractice. J Viral Hepat,2012,19(6):377-386. [89] Liaw YF,Gane E,Leung N,et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology,2009,136(2):486-495. [90] Lai CL,Gane E, Liaw YF,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med,2007,357(25):2576-2588. [91] 任江波,王宇,李红艺, 等. 替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析. 中华肝脏病杂志,2012,20(9):641-643. [92] Chan HL,Wong VW,Tse AM,et al.Serum hepatitis B surfaceantigen quantitation can reflect hepatitis Bvirus in the liver and predict treatment response. Clin GastroenterolHepatol,2007,5(12):1462-1468. [93] Ning Q,Han M,Sun Y,et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial (OSST trial). J Hepatol,2014. [94] Xie Q,Zhou HJ,Bai XF,et al. A Randomized,open-label clinical study of combined peginterferon alfa-2a(40KD) and entecavir treatment for HBeAg-positive chronic hepatitis B. Clin Infect Dis,2014. |
[1] | chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819. |
[2] | Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823. |
[3] | Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827. |
[4] | patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831. |
[5] | chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835. |
[6] | Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839. |
[7] | Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929. |
[8] | Ding Wenjin, Fan Jiangao.. Management of complications associated with cholestatic liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 938-940. |
[9] | Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616. |
[10] | Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619. |
[11] | . [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635. |
[12] | Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647. |
[13] | Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651. |
[14] | Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655. |
[15] | Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||